secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001437749-25-013848
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Health Q1 revenue down 14% to $149.9M; net loss narrows to $67.6M; signs $225M Labcorp asset sale
--------------------------------------------------------------------------------

- Revenue $149.9M vs $173.7M YoY; net loss $0.10 per share vs $0.12 per share.
- Signed definitive agreement to sell oncology testing assets to Labcorp for up to $225M ($192.5M at close + $32.5M earnout); expected close H2 2025.
- Board authorized additional $100M for stock buyback (total $200M); ~$40.2M repurchased under prior program since July 2024.
- Post-quarter: exchanged $159.2M convertible notes for 121.4M shares + $63.5M cash.
- Collaboration with Entera Bio for oral GLP-1/glucagon tablet; OPKO purchased 3.7M Entera shares at $2.17/share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000143774925013848/0001437749-25-013848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000143774925013848/opk20250417_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-013848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer